Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
Complete Genome Sequences of Caldicellulosiruptor sp. Strain Rt8.B8, Caldicellulosiruptor sp. Strain Wai35.B1, and "Thermoanaerobacter cellulolyticus".

Genome announcements

Lee LL, Izquierdo JA, Blumer-Schuette SE, Zurawski JV, Conway JM, Cottingham RW, Huntemann M, Copeland A, Chen IM, Kyrpides N, Markowitz V, Palaniappan K, Ivanova N, Mikhailova N, Ovchinnikova G, Andersen E, Pati A, Stamatis D, Reddy TB, Shapiro N, Nordberg HP, Cantor MN, Hua SX, Woyke T, Kelly RM.
PMID: 25977428
Genome Announc. 2015 May 14;3(3). doi: 10.1128/genomeA.00440-15.

The genus Caldicellulosiruptor contains extremely thermophilic, cellulolytic bacteria capable of lignocellulose deconstruction. Currently, complete genome sequences for eleven Caldicellulosiruptor species are available. Here, we report genome sequences for three additional Caldicellulosiruptor species: Rt8.B8 DSM 8990 (New Zealand), Wai35.B1 DSM...

Cite
Lee LL, Izquierdo JA, Blumer-Schuette SE, et al. Complete Genome Sequences of Caldicellulosiruptor sp. Strain Rt8.B8, Caldicellulosiruptor sp. Strain Wai35.B1, and "Thermoanaerobacter cellulolyticus". Genome Announc. 2015;3(3)doi: 10.1128/genomeA.00440-15.
Lee, L. L., Izquierdo, J. A., Blumer-Schuette, S. E., Zurawski, J. V., Conway, J. M., Cottingham, R. W., Huntemann, M., Copeland, A., Chen, I. M., Kyrpides, N., Markowitz, V., Palaniappan, K., Ivanova, N., Mikhailova, N., Ovchinnikova, G., Andersen, E., Pati, A., Stamatis, D., Reddy, T. B., Shapiro, N., Nordberg, H. P., Cantor, M. N., Hua, S. X., Woyke, T., & Kelly, R. M. (2015). Complete Genome Sequences of Caldicellulosiruptor sp. Strain Rt8.B8, Caldicellulosiruptor sp. Strain Wai35.B1, and "Thermoanaerobacter cellulolyticus". Genome announcements, 3(3), . https://doi.org/10.1128/genomeA.00440-15
Lee, Laura L, et al. "Complete Genome Sequences of Caldicellulosiruptor sp. Strain Rt8.B8, Caldicellulosiruptor sp. Strain Wai35.B1, and "Thermoanaerobacter cellulolyticus"." Genome announcements vol. 3,3 (2015). doi: https://doi.org/10.1128/genomeA.00440-15
Lee LL, Izquierdo JA, Blumer-Schuette SE, Zurawski JV, Conway JM, Cottingham RW, Huntemann M, Copeland A, Chen IM, Kyrpides N, Markowitz V, Palaniappan K, Ivanova N, Mikhailova N, Ovchinnikova G, Andersen E, Pati A, Stamatis D, Reddy TB, Shapiro N, Nordberg HP, Cantor MN, Hua SX, Woyke T, Kelly RM. Complete Genome Sequences of Caldicellulosiruptor sp. Strain Rt8.B8, Caldicellulosiruptor sp. Strain Wai35.B1, and "Thermoanaerobacter cellulolyticus". Genome Announc. 2015 May 14;3(3). doi: 10.1128/genomeA.00440-15. PMID: 25977428; PMCID: PMC4432334.
Copy Download .nbib Format: NLM
A blue luminescent MOF as a rapid turn-off/turn-on detector for H2O, O2 and CH2Cl2, MeCN: ∞³[Ce(Im)3ImH]·ImH.

Dalton transactions (Cambridge, England : 2003)

Meyer LV, Schönfeld F, Zurawski A, Mai M, Feldmann C, Müller-Buschbaum K.
PMID: 25623757
Dalton Trans. 2015 Mar 07;44(9):4070-9. doi: 10.1039/c4dt03578j.

The blue emitting luminescent MOF ∞³[Ce(Im)3ImH]·ImH forms a 3D-framework with Kagomé net topology. The framework exhibits an intense blue luminescence which can be retained upon activation of the MOF with the formula ∞³[Ce(Im)3ImH]. The luminescence is metal-based due to...

Cite
Meyer LV, Schönfeld F, Zurawski A, et al. A blue luminescent MOF as a rapid turn-off/turn-on detector for H2O, O2 and CH2Cl2, MeCN: ∞³[Ce(Im)3ImH]·ImH. Dalton Trans. 2015;44(9):4070-9doi: 10.1039/c4dt03578j.
Meyer, L. V., Schönfeld, F., Zurawski, A., Mai, M., Feldmann, C., & Müller-Buschbaum, K. (2015). A blue luminescent MOF as a rapid turn-off/turn-on detector for H2O, O2 and CH2Cl2, MeCN: ∞³[Ce(Im)3ImH]·ImH. Dalton transactions (Cambridge, England : 2003), 44(9), 4070-9. https://doi.org/10.1039/c4dt03578j
Meyer, L V, et al. "A blue luminescent MOF as a rapid turn-off/turn-on detector for H2O, O2 and CH2Cl2, MeCN: ∞³[Ce(Im)3ImH]·ImH." Dalton transactions (Cambridge, England : 2003) vol. 44,9 (2015): 4070-9. doi: https://doi.org/10.1039/c4dt03578j
Meyer LV, Schönfeld F, Zurawski A, Mai M, Feldmann C, Müller-Buschbaum K. A blue luminescent MOF as a rapid turn-off/turn-on detector for H2O, O2 and CH2Cl2, MeCN: ∞³[Ce(Im)3ImH]·ImH. Dalton Trans. 2015 Mar 07;44(9):4070-9. doi: 10.1039/c4dt03578j. PMID: 25623757.
Copy Download .nbib Format: NLM
Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy.

Therapeutic advances in neurological disorders

Hoepner R, Dahlhaus S, Kollar S, Zurawski B, Chan A, Kleiter I, Gold R, Hellwig K.
PMID: 24409198
Ther Adv Neurol Disord. 2014 Jan;7(1):3-6. doi: 10.1177/1756285613503515.

OBJECTIVE: Little is known about seizures in natalizumab-associated progressive multifocal leukoencephalopathy (NAT-PML).METHODS: A review of clinical records of 15 NAT-PML patients with multiple sclerosis (MS) treated at a German university hospital.RESULTS: Some 53% (8/15) of our patients developed seizures...

Cite
Hoepner R, Dahlhaus S, Kollar S, et al. Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy. Ther Adv Neurol Disord. 2014;7(1):3-6doi: 10.1177/1756285613503515.
Hoepner, R., Dahlhaus, S., Kollar, S., Zurawski, B., Chan, A., Kleiter, I., Gold, R., & Hellwig, K. (2014). Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy. Therapeutic advances in neurological disorders, 7(1), 3-6. https://doi.org/10.1177/1756285613503515
Hoepner, Robert, et al. "Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy." Therapeutic advances in neurological disorders vol. 7,1 (2014): 3-6. doi: https://doi.org/10.1177/1756285613503515
Hoepner R, Dahlhaus S, Kollar S, Zurawski B, Chan A, Kleiter I, Gold R, Hellwig K. Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy. Ther Adv Neurol Disord. 2014 Jan;7(1):3-6. doi: 10.1177/1756285613503515. PMID: 24409198; PMCID: PMC3886383.
Copy Download .nbib Format: NLM
[Not available].

Laryngo- rhino- otologie

Zurawski A, Brors D.
PMID: 27517104
Laryngorhinootologie. 2016 Apr;95(4):238-9. doi: 10.1055/s-0035-1552539.

No abstract available.

Cite
Zurawski A, Brors D. Peritonsillarabszess. Nadelaspiration ist effective Erstlinientherapie. [Not available]. Laryngorhinootologie. 2016;95(4):238-9doi: 10.1055/s-0035-1552539.
Zurawski, A., & Brors, D. (2016). Peritonsillarabszess. Nadelaspiration ist effective Erstlinientherapie. [Not available]. Laryngo- rhino- otologie, 95(4), 238-9. https://doi.org/10.1055/s-0035-1552539
Zurawski, Alexandra, and Brors, Dominik. "Peritonsillarabszess. Nadelaspiration ist effective Erstlinientherapie." [Not available]. Laryngo- rhino- otologie vol. 95,4 (2016): 238-9. doi: https://doi.org/10.1055/s-0035-1552539
Zurawski A, Brors D. Peritonsillarabszess. Nadelaspiration ist effective Erstlinientherapie. [Not available]. Laryngorhinootologie. 2016 Apr;95(4):238-9. doi: 10.1055/s-0035-1552539. German. PMID: 27517104.
Copy Download .nbib Format: NLM
Structures of the genes for the beta and epsilon subunits of spinach chloroplast ATPase indicate a dicistronic mRNA and an overlapping translation stop/start signal.

Proceedings of the National Academy of Sciences of the United States of America

Zurawski G, Bottomley W, Whitfeld PR.
PMID: 16593238
Proc Natl Acad Sci U S A. 1982 Oct;79(20):6260-4. doi: 10.1073/pnas.79.20.6260.

A 2,4-kilobase-pair region of spinach chloroplast DNA adjacent to the gene for the large subunit of ribulosebisphosphate carboxylase has been analyzed by RNA hybridization, in vitro transcription/translation, and DNA sequence determination. The analysis indicates that this region carries the...

Cite
Zurawski G, Bottomley W, Whitfeld PR. Structures of the genes for the beta and epsilon subunits of spinach chloroplast ATPase indicate a dicistronic mRNA and an overlapping translation stop/start signal. Proc Natl Acad Sci U S A. 1982;79(20):6260-4doi: 10.1073/pnas.79.20.6260.
Zurawski, G., Bottomley, W., & Whitfeld, P. R. (1982). Structures of the genes for the beta and epsilon subunits of spinach chloroplast ATPase indicate a dicistronic mRNA and an overlapping translation stop/start signal. Proceedings of the National Academy of Sciences of the United States of America, 79(20), 6260-4. https://doi.org/10.1073/pnas.79.20.6260
Zurawski, G, et al. "Structures of the genes for the beta and epsilon subunits of spinach chloroplast ATPase indicate a dicistronic mRNA and an overlapping translation stop/start signal." Proceedings of the National Academy of Sciences of the United States of America vol. 79,20 (1982): 6260-4. doi: https://doi.org/10.1073/pnas.79.20.6260
Zurawski G, Bottomley W, Whitfeld PR. Structures of the genes for the beta and epsilon subunits of spinach chloroplast ATPase indicate a dicistronic mRNA and an overlapping translation stop/start signal. Proc Natl Acad Sci U S A. 1982 Oct;79(20):6260-4. doi: 10.1073/pnas.79.20.6260. PMID: 16593238; PMCID: PMC347100.
Copy Download .nbib Format: NLM
Melamine-melem adduct phases: investigating the thermal condensation of melamine.

Chemistry (Weinheim an der Bergstrasse, Germany)

Sattler A, Pagano S, Zeuner M, Zurawski A, Gunzelmann D, Senker J, Müller-Buschbaum K, Schnick W.
PMID: 19876968
Chemistry. 2009 Dec 07;15(47):13161-70. doi: 10.1002/chem.200901518.

By studying the thermal condensation of melamine, we have identified three solid molecular adducts consisting of melamine C(3)N(3)(NH(2))(3) and melem C(6)N(7)(NH(2))(3) in differing molar ratios. We solved the crystal structure of 2 C(3)N(3)(NH(2))(3)C(6)N(7)(NH(2))(3) (1; C2/c; a=21.526(4), b=12.595(3), c=6.8483(14) A;...

Cite
Sattler A, Pagano S, Zeuner M, et al. Melamine-melem adduct phases: investigating the thermal condensation of melamine. Chemistry. 2009;15(47):13161-70doi: 10.1002/chem.200901518.
Sattler, A., Pagano, S., Zeuner, M., Zurawski, A., Gunzelmann, D., Senker, J., Müller-Buschbaum, K., & Schnick, W. (2009). Melamine-melem adduct phases: investigating the thermal condensation of melamine. Chemistry (Weinheim an der Bergstrasse, Germany), 15(47), 13161-70. https://doi.org/10.1002/chem.200901518
Sattler, Andreas, et al. "Melamine-melem adduct phases: investigating the thermal condensation of melamine." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 15,47 (2009): 13161-70. doi: https://doi.org/10.1002/chem.200901518
Sattler A, Pagano S, Zeuner M, Zurawski A, Gunzelmann D, Senker J, Müller-Buschbaum K, Schnick W. Melamine-melem adduct phases: investigating the thermal condensation of melamine. Chemistry. 2009 Dec 07;15(47):13161-70. doi: 10.1002/chem.200901518. PMID: 19876968.
Copy Download .nbib Format: NLM
Callus formation from protoplasts of a maize cell culture.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik

Chourey PS, Zurawski DB.
PMID: 24276566
Theor Appl Genet. 1981 Nov;59(6):341-4. doi: 10.1007/BF00276446.

A finely dispersed cell suspension culture from the friable callus of the 'Black Mexican Sweet' line of maize was obtained. Protoplasts from this cell culture, when grown in a simplified medium described here, showed sustained cell divisions and gave...

Cite
Chourey PS, Zurawski DB. Callus formation from protoplasts of a maize cell culture. Theor Appl Genet. 1981;59(6):341-4doi: 10.1007/BF00276446.
Chourey, P. S., & Zurawski, D. B. (1981). Callus formation from protoplasts of a maize cell culture. TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik, 59(6), 341-4. https://doi.org/10.1007/BF00276446
Chourey, P S, and Zurawski, D B. "Callus formation from protoplasts of a maize cell culture." TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik vol. 59,6 (1981): 341-4. doi: https://doi.org/10.1007/BF00276446
Chourey PS, Zurawski DB. Callus formation from protoplasts of a maize cell culture. Theor Appl Genet. 1981 Nov;59(6):341-4. doi: 10.1007/BF00276446. PMID: 24276566.
Copy Download .nbib Format: NLM
1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant .

ACS medicinal chemistry letters

Huggins WM, Minrovic BM, Corey BW, Jacobs AC, Melander RJ, Sommer RD, Zurawski DV, Melander C.
PMID: 28105270
ACS Med Chem Lett. 2016 Nov 12;8(1):27-31. doi: 10.1021/acsmedchemlett.6b00296. eCollection 2017 Jan 12.

With only two new classes of antibiotics developed in the last 40 years, novel antibiotics are desperately needed to combat the growing problem of multidrug-resistant and extensively drug resistant bacteria, particularly Gram-negative bacteria. Described in this letter is the...

Cite
Huggins WM, Minrovic BM, Corey BW, et al. 1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant . ACS Med Chem Lett. 2016;8(1):27-31doi: 10.1021/acsmedchemlett.6b00296.
Huggins, W. M., Minrovic, B. M., Corey, B. W., Jacobs, A. C., Melander, R. J., Sommer, R. D., Zurawski, D. V., & Melander, C. (2017). 1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant . ACS medicinal chemistry letters, 8(1), 27-31. https://doi.org/10.1021/acsmedchemlett.6b00296
Huggins, William M, et al. "1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant ." ACS medicinal chemistry letters vol. 8,1 (2017): 27-31. doi: https://doi.org/10.1021/acsmedchemlett.6b00296
Huggins WM, Minrovic BM, Corey BW, Jacobs AC, Melander RJ, Sommer RD, Zurawski DV, Melander C. 1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant . ACS Med Chem Lett. 2016 Nov 12;8(1):27-31. doi: 10.1021/acsmedchemlett.6b00296. eCollection 2017 Jan 12. PMID: 28105270; PMCID: PMC5238477.
Copy Download .nbib Format: NLM
Interrater Reliability of the Modified Ashworth Scale with Standardized Movement Speeds: A Pilot Study.

Physiotherapy Canada. Physiotherapie Canada

Zurawski E, Behm K, Dunlap C, Koo J, Ismail F, Boulias C, Reid S, Phadke CP.
PMID: 31762545
Physiother Can. 2019;71(4):348-354. doi: 10.3138/ptc-2018-0086.

No abstract available.

Cite
Zurawski E, Behm K, Dunlap C, et al. Interrater Reliability of the Modified Ashworth Scale with Standardized Movement Speeds: A Pilot Study. Physiother Can. 2019;71(4):348-354doi: 10.3138/ptc-2018-0086.
Zurawski, E., Behm, K., Dunlap, C., Koo, J., Ismail, F., Boulias, C., Reid, S., & Phadke, C. P. (2019). Interrater Reliability of the Modified Ashworth Scale with Standardized Movement Speeds: A Pilot Study. Physiotherapy Canada. Physiotherapie Canada, 71(4), 348-354. https://doi.org/10.3138/ptc-2018-0086
Zurawski, Erica, et al. "Interrater Reliability of the Modified Ashworth Scale with Standardized Movement Speeds: A Pilot Study." Physiotherapy Canada. Physiotherapie Canada vol. 71,4 (2019): 348-354. doi: https://doi.org/10.3138/ptc-2018-0086
Zurawski E, Behm K, Dunlap C, Koo J, Ismail F, Boulias C, Reid S, Phadke CP. Interrater Reliability of the Modified Ashworth Scale with Standardized Movement Speeds: A Pilot Study. Physiother Can. 2019;71(4):348-354. doi: 10.3138/ptc-2018-0086. PMID: 31762545; PMCID: PMC6855344.
Copy Download .nbib Format: NLM
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.

ESMO open

Ledermann JA, Zurawski B, Raspagliesi F, De Giorgi U, Arranz Arija J, Romeo Marin M, Lisyanskaya A, Póka RL, Markowska J, Cebotaru C, Casado Herraez A, Colombo N, Kutarska E, Hall M, Jacobs A, Ahrens-Fath I, Baumeister H, Zurlo A, Sehouli J.
PMID: 34920291
ESMO Open. 2021 Dec 14;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 14.

BACKGROUND: Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to evaluate the efficacy and safety of switch maintenance therapy with gatipotuzumab in patients with TA-MUC1-positive recurrent ovarian, fallopian tube,...

Cite
Ledermann JA, Zurawski B, Raspagliesi F, et al. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open. 2021;7(1):100311doi: 10.1016/j.esmoop.2021.100311.
Ledermann, J. A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R. L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., & Sehouli, J. (2021). Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO open, 7(1), 100311. https://doi.org/10.1016/j.esmoop.2021.100311
Ledermann, J A, et al. "Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study." ESMO open vol. 7,1 (2021): 100311. doi: https://doi.org/10.1016/j.esmoop.2021.100311
Ledermann JA, Zurawski B, Raspagliesi F, De Giorgi U, Arranz Arija J, Romeo Marin M, Lisyanskaya A, Póka RL, Markowska J, Cebotaru C, Casado Herraez A, Colombo N, Kutarska E, Hall M, Jacobs A, Ahrens-Fath I, Baumeister H, Zurlo A, Sehouli J. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open. 2021 Dec 14;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 14. PMID: 34920291; PMCID: PMC8685985.
Copy Download .nbib Format: NLM
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.

ESMO open

Ledermann JA, Zurawski B, Raspagliesi F, De Giorgi U, Arranz Arija J, Romeo Marin M, Lisyanskaya A, Póka RL, Markowska J, Cebotaru C, Casado Herraez A, Colombo N, Kutarska E, Hall M, Jacobs A, Ahrens-Fath I, Baumeister H, Zurlo A, Sehouli J.
PMID: 34920291
ESMO Open. 2021 Dec 14;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 14.

BACKGROUND: Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to evaluate the efficacy and safety of switch maintenance therapy with gatipotuzumab in patients with TA-MUC1-positive recurrent ovarian, fallopian tube,...

Cite
Ledermann JA, Zurawski B, Raspagliesi F, et al. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open. 2021;7(1):100311doi: 10.1016/j.esmoop.2021.100311.
Ledermann, J. A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R. L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., & Sehouli, J. (2021). Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO open, 7(1), 100311. https://doi.org/10.1016/j.esmoop.2021.100311
Ledermann, J A, et al. "Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study." ESMO open vol. 7,1 (2021): 100311. doi: https://doi.org/10.1016/j.esmoop.2021.100311
Ledermann JA, Zurawski B, Raspagliesi F, De Giorgi U, Arranz Arija J, Romeo Marin M, Lisyanskaya A, Póka RL, Markowska J, Cebotaru C, Casado Herraez A, Colombo N, Kutarska E, Hall M, Jacobs A, Ahrens-Fath I, Baumeister H, Zurlo A, Sehouli J. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open. 2021 Dec 14;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 14. PMID: 34920291; PMCID: PMC8685985.
Copy Download .nbib Format: NLM
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

ESMO open

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T.
PMID: 34864501
ESMO Open. 2021 Dec 02;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 02.

No abstract available.

Cite
Reck M, Ciuleanu TE, Cobo M, et al. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open. 2021;6(6):100345doi: 10.1016/j.esmoop.2021.100345.
Reck, M., Ciuleanu, T. E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P. J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D. P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., & John, T. (2021). Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO open, 6(6), 100345. https://doi.org/10.1016/j.esmoop.2021.100345
Reck, M, et al. "Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]." ESMO open vol. 6,6 (2021): 100345. doi: https://doi.org/10.1016/j.esmoop.2021.100345
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]. ESMO Open. 2021 Dec 02;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 02. PMID: 34864501; PMCID: PMC8649668.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries